B-4T2001 is under clinical development by Bio4t2 and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how B-4T2001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

B-4T2001 overview

B4T2-001 is under development for the treatment of metastatic solid tumors including gastric or gastroesophageal junction adenocarcinoma, pancreatic cancer, non-small cell lung cancer, breast cancer and colorectal cancer. The therapeutic candidate comprises T cells genetically modified to express chimeric antigen receptors (CAR) targeting tumor associated antigens. It is being developed based on PrismCore, an artificial intelligence (AI) platform. It is administered through parenteral route.

Bio4t2 overview

Bio4t2 is a preclinical biopharmaceutical company developing single-target and combo-therapeutic CAR-T therapies targeting solid tumors. Bio4t2 is headquartered in San Diego, California, the US.

For a complete picture of B-4T2001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.